產(chǎn)品名稱(chēng) |
116 [Anti PDGF Hybridoma #116] |
商品貨號 |
B163543 |
Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
Cell Type |
hybridoma: B lymphocyte |
Product Format |
frozen |
Morphology |
lymphoblast |
Culture Properties |
suspension |
Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
Applications |
The antibody is specific for the B chain of PDGF v-sis. |
Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
Derivation |
Animals were immunized with affinity purified PDGF B v-sis. Spleen cells were fused with Sp2/0-Ag14 myeloma cells. |
Genes Expressed |
immunoglobulin; monoclonal antibody; against platelet derived growth factor B chain (PDGF B, v-sis form) |
Cellular Products |
immunoglobulin; monoclonal antibody; against platelet derived growth factor B chain (PDGF B, v-sis form) |
Tumorigenic |
Yes |
Effects |
Yes, forms ascites in pristane primed BALB/c mice |
Comments |
Animals were immunized with affinity purified PDGF B v-sis. Spleen cells were fused with Sp2/0-Ag14 myeloma cells. The antibody is specific for the B chain of PDGF v-sis. |
Complete Growth Medium |
Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 90%; heat-inactivated fetal bovine serum, 10%
|
Subculturing |
Medium Renewal: Every 2 to 3 days Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml. |
Cryopreservation |
fetal bovine serum, 90%; DMSO, 10% |
Isotype |
IgG2a |
Name of Depositor |
Amgen, Inc. |
Deposited As |
mouse (B cell); mouse (myeloma) |
U.S. Patent Number |
|
References |
Thomason AR, Nicolson MA. Methods for purification of platelet-derived growth factor. US Patent 5,175,255 dated Dec 29 1992
|